intragastric balloon system (Orbera Intragastric Balloon System, ReShape Integrated Dual Balloon System)
Jump to navigation
Jump to search
Indications
- treatment of obesity
Laboratory
- AGA recommends against screening for nutritional deficiencies[3]
Complications
- balloons can erode gastric mucosa[3]
- reports of at least 5 deaths within days or weeks of the procedure[1][2]
Management
- lifestyle changes should accompany intragastric balloon therapy
- proton-pump inhibitors should be given prophylactically[3]
Notes
- Allurion intragastric balloon (formerly the Elipse, Allurion Technologies) is swallowed, requiring no surgery or endoscopic placement, shows high efficacy in achieving weight loss & an improved metabolic profile, with fewer adverse events than reported with other available gastric balloons[4]
More general terms
References
- ↑ 1.0 1.1 FDA Safety Alert. Aug 10, 2017 Liquid-filled Intragastric Balloon Systems: Letter to Healthcare Providers - Potential Risks. https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm570916.htm
- ↑ 2.0 2.1 FDA Safety Alert. June 4, 2018 Liquid-filled Intragastric Balloons by Apollo Endosurgery and ReShape Lifesciences: Letter to Health Care Providers
New Labeling About Potential Risks. https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm609761.htm - ↑ 3.0 3.1 3.2 3.3 Muniraj T, Day LW, Teigen LM et al AGA Clinical Practice Guidelines on Intragastric Balloons in the Management of Obesity. Gastroenterology. 2021 160(5):1799-1898. April 1 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33832655 https://www.gastrojournal.org/article/S0016-5085(21)00477-7/fulltext
- ↑ 4.0 4.1 Melville NA Swallowable Intragastric Balloon Shows Significant Weight Loss. Medscape. Jan 12, 2022 https://www.medscape.com/viewarticle/966489